Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .
Source:: Reuters – Business News
Newswire
- [ April 2, 2025 ] Quoin Pharmaceuticals (NASDAQ: QNRX) Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient Newsmakers
- [ April 2, 2025 ] Innovation Beverage Group (NASDAQ: IBG) Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation’s Largest Beverage Alcohol Distributors Newsmakers
- [ March 25, 2025 ] Predictive Oncology (NASDAQ: POAI) Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary Newsmakers
- [ March 25, 2025 ] Tenon Medical (NASDAQ:TNON) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion Newsmakers
- [ March 24, 2025 ] Damon Inc. (NASDAQ: DMN) Announces Closing of Upsized $16.5 Million Underwritten Public Offering Newsmakers
- [ March 18, 2025 ] ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil CEO Interview
- [ March 17, 2025 ] Hyperfine (NASDAQ: HYPR) and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation Newsmakers
- [ March 13, 2025 ] FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD) Newsmakers
- [ March 13, 2025 ] ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Newsmakers
- [ March 13, 2025 ] “Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Aerospace & Defense
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.